S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:TLRY

Tilray - TLRY Stock Forecast, Price & News

$4.03
+0.18 (+4.68%)
(As of 08/12/2022 04:34 PM ET)
Add
Compare
Today's Range
$3.84
$4.06
50-Day Range
$3.11
$4.30
52-Week Range
$3.00
$14.27
Volume
23.39 million shs
Average Volume
29.19 million shs
Market Capitalization
$2.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.78

Tilray MarketRank™ Forecast

Analyst Rating
Hold
2.08 Rating Score
Upside/​Downside
68.3% Upside
$6.78 Price Target
Short Interest
Healthy
13.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of Tilray in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1.08 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.18) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Consumer Staples Sector

84th out of 147 stocks

Medicinals & Botanicals Industry

5th out of 14 stocks

TLRY stock logo

About Tilray (NASDAQ:TLRY) Stock

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Cantor Fitzgerald decreased their target price on shares of Tilray from $5.75 to $4.15 and set a "neutral" rating for the company in a research report on Tuesday, August 2nd. Barclays decreased their target price on shares of Tilray from $8.50 to $4.50 and set an "underweight" rating for the company in a research report on Wednesday, April 20th. Canaccord Genuity Group decreased their target price on shares of Tilray from $9.00 to $7.00 in a research report on Wednesday, June 15th. Benchmark downgraded shares of Tilray from a "hold" rating to a "sell" rating and set a $3.00 target price for the company. in a research report on Friday, July 29th. Finally, Alliance Global Partners decreased their target price on shares of Tilray from $8.00 to $5.50 and set a "neutral" rating for the company in a research report on Monday, May 2nd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $7.15.

Tilray Stock Up 4.4 %

Shares of TLRY traded up $0.17 during trading hours on Friday, reaching $4.02. The stock had a trading volume of 1,159,559 shares, compared to its average volume of 35,095,960. Tilray has a 12 month low of $3.00 and a 12 month high of $14.33. The firm has a 50-day simple moving average of $3.53 and a 200 day simple moving average of $4.97. The company has a current ratio of 2.87, a quick ratio of 1.99 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -4.46 and a beta of 2.57.

Tilray (NASDAQ:TLRY - Get Rating) last issued its earnings results on Thursday, July 28th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.27). Tilray had a negative return on equity of 4.14% and a negative net margin of 71.52%. The firm had revenue of $153.30 million during the quarter, compared to the consensus estimate of $151.53 million. During the same quarter in the prior year, the business earned ($0.11) earnings per share. Tilray's revenue for the quarter was up 7.8% on a year-over-year basis. Equities research analysts predict that Tilray will post -0.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Tilray news, Director Brendan Kennedy sold 350,000 shares of the firm's stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $3.09, for a total transaction of $1,081,500.00. Following the transaction, the director now directly owns 7,624,196 shares in the company, valued at approximately $23,558,765.64. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.17% of the stock is owned by company insiders.

Receive TLRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tilray and its competitors with MarketBeat's FREE daily newsletter.

TLRY Stock News Headlines

Cronos Group Inc's Revenues Are Up, Is It Time to Buy? (TLRY)
Cronos Group's revenues exceeded expectations last quarter which sent its shares climbing. Is the company able to make a repeat performance in Q2'22?
Brokerages Set Tilray Inc (NASDAQ:TLRY) Price Target at $7.15
Apple’s Next “Star Product” Could Replace The iPhone?
Apple's next "star product" could be its most profitable yet & may dominate a fast-growing new industry that Morgan Stanley projects will be worth a stunning $10 trillion! The new “profit machine” could hand early investors a $190,717 payday. How can you lock in your shot to 20X your money?  See Here. pixel
51-Year Market Veteran Reveals Stunning "Crash Profit Trades"
In the last bear market, Dr. Martin Weiss and his team found historical examples of “Crash Profit Trades” that could have produced gains of 103%, 110%, 124%, 134%, 147%, 150%, 157%, 163%, 168%, 174%, 195%, 198%, 243%, and 293%. Now, in 2022, even larger profits have been possible. Show me Crash Profit Trades. pixel
Benchmark Lowers Tilray (NASDAQ:TLRY) to Sell
Cowen Trims Tilray (NASDAQ:TLRY) Target Price to $9.00
Why Tilray Stock Was a Laggard on Friday
See More Headlines
Receive TLRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tilray and its competitors with MarketBeat's FREE daily newsletter.

TLRY Company Calendar

Last Earnings
7/28/2022
Today
8/12/2022
Next Earnings (Estimated)
10/06/2022
Fiscal Year End
5/31/2023

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:TLRY
Fax
N/A
Employees
2,100
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.78
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+68.3%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
12 Analysts

Profitability

Net Income
$-476,800,000.00
Pretax Margin
-70.13%

Debt

Sales & Book Value

Annual Sales
$628.37 million
Book Value
$8.34 per share

Miscellaneous

Free Float
519,387,000
Market Cap
$2.16 billion
Optionable
Optionable
Beta
2.57














TLRY Stock - Frequently Asked Questions

Should I buy or sell Tilray stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TLRY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLRY, but not buy additional shares or sell existing shares.
View TLRY analyst ratings
or view top-rated stocks.

What is Tilray's stock price forecast for 2022?

12 brokers have issued twelve-month price objectives for Tilray's shares. Their TLRY share price forecasts range from $3.00 to $12.00. On average, they predict the company's stock price to reach $6.78 in the next twelve months. This suggests a possible upside of 69.5% from the stock's current price.
View analysts price targets for TLRY
or view top-rated stocks among Wall Street analysts.

How have TLRY shares performed in 2022?

Tilray's stock was trading at $7.03 at the beginning of 2022. Since then, TLRY shares have decreased by 43.1% and is now trading at $4.00.
View the best growth stocks for 2022 here
.

When is Tilray's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 6th 2022.
View our TLRY earnings forecast
.

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) announced its quarterly earnings results on Thursday, July, 28th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.27. The business earned $153.30 million during the quarter, compared to the consensus estimate of $151.53 million. Tilray had a negative net margin of 71.52% and a negative trailing twelve-month return on equity of 4.14%. Tilray's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.11) earnings per share.

What is Brendan Kennedy's approval rating as Tilray's CEO?

32 employees have rated Tilray Chief Executive Officer Brendan Kennedy on Glassdoor.com. Brendan Kennedy has an approval rating of 51% among the company's employees. This puts Brendan Kennedy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Block (SQ).

When did Tilray IPO?

(TLRY) raised $135 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company acted as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

What is Tilray's stock symbol?

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Who are Tilray's major shareholders?

Tilray's stock is owned by many different institutional and retail investors. Top institutional shareholders include Public Sector Pension Investment Board (0.23%), Mirae Asset Global Investments Co. Ltd. (0.22%), AdvisorShares Investments LLC (0.19%), Simplex Trading LLC (0.00%), TD Asset Management Inc. (0.17%) and California Public Employees Retirement System (0.15%). Insiders that own company stock include Brendan Kennedy, Carl A Merton, Christine StClare, James R Meiers, Maryscott Greenwood and Michael Auerbach.
View institutional ownership trends
.

How do I buy shares of Tilray?

Shares of TLRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tilray's stock price today?

One share of TLRY stock can currently be purchased for approximately $4.00.

How much money does Tilray make?

Tilray (NASDAQ:TLRY) has a market capitalization of $2.15 billion and generates $628.37 million in revenue each year. The company earns $-476,800,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does Tilray have?

The company employs 2,100 workers across the globe.

How can I contact Tilray?

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The official website for the company is www.tilray.com. The company can be reached via phone at 206-432-9325.

This page (NASDAQ:TLRY) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.